



Vaccine Development for Toxoplasmosis

Guest Editor:

Dr. Margarida Borges

UCIBIO/REQUIMTE,
Departamento de Ciências
Biológicas, Faculdade de
Farmácia, Universidade do Porto,
Porto, Portugal

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

Dear Colleagues,

Toxoplasmosis is a disease caused by *Toxoplasma gondii*, exerting a high impact on human health worldwide. This disease may affect immunocompromised individuals causing serious health issues such as encephalitis, pneumonia and even death.

Current treatment options are old, limited, and possess toxic side effects. At present, no vaccine exists to prevent human disease caused by *T. gondii*, thus demand for a vaccine presenting complete and lasting protection against toxoplasmosis is urgent.

This research topic will include contributions that highlight advances and challenges regarding the development of a novel prophylactic vaccine for toxoplasmosis. Research areas in this field may include (but are not limited to) the following:

nanovaccines development; establishment of *in vitro* and/or *in vivo* study models; immune responses; nasal immunization; identification of immune mechanisms induced by vaccination and related to protection against infection; vaccines in congenital toxoplasmosis.

I am pleased to invite you to contribute with original research articles or reviews.

Dr. Margarida Borges

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com